Calcified Tissue International

, Volume 60, Issue 2, pp 135–138 | Cite as

Perspectives for the Treatment of Osteoporosis


Key words

Calcitonin Parathyroid hormone Bisphosphonates oligoelements Flavones Promethazine Potassium bicarbonate Thiazides Vitamin K Calcium Nonsteroidal antiinflammatory agents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reginster JY, Deroisy R, Albert A, Denis D, Lecart MP, Collette J, Franchimont P (1989) Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics. J Clin Invest 83:1073–1077PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Perez Cano R, Montoya MJ, Moruno R, Vazquez A, Galan F, Garrido M (1989) Calcitonin reserve in healthy women and patients with postmenopausal osteoporosis. Calcif Tissue Int 45:203–208PubMedCrossRefGoogle Scholar
  3. 3.
    Chambers TJ, Chambers JC, Symonds J, Darby JA (1986) The effect of human calcitonin on the cytoplasmic spreading of rat osteoclast. J Clin Endocrinol Metab 63:1080–1085PubMedCrossRefGoogle Scholar
  4. 4.
    Chambers TJ, Fuller K, Darby JA (1987) Hormonal regulation of acid phosphatase release by osteoclast disaggregated from neonatal rat bone. J Cell Physiol 132:90–96PubMedCrossRefGoogle Scholar
  5. 5.
    Hall GE, Kenny AD (1987) Role of carbonic anhydrase in bone resorption: effect of acetazolamide on basal and parathyroid hormone-induced bone metabolism. Calcif Tissue Int 40:212–218PubMedCrossRefGoogle Scholar
  6. 6.
    Kaji H, Sugimoto T, Miyauchi A, Fukase M, Tezuka K, Hakeda Y, Kumegawa M, Chihara K (1994) Calcitonin inhibits osteopontin mRNA expression in isolated rabbit osteoclasts. Endocrinology 135:484–487PubMedGoogle Scholar
  7. 7.
    Ito N, Yamazaki H, Nakazaki M, Miyahara T, Kozuka H, Sudo H (1987) Response of osteoblastic clonal cell line (MC3T3-E1) to (Asu 1,7) Eel calcitonin at a specific cell density or differentiation stage. Calcif Tissue Int 40:200–205PubMedCrossRefGoogle Scholar
  8. 8.
    Farley JR, Hall SL, Herring S, Tarbaux NM (1992) Two biochemical indices of mouse bone formation are increased, in vivo, in response to calcitonin. Calcif Tissue Int 50:67–73PubMedCrossRefGoogle Scholar
  9. 9.
    Kobayashi T, Sugimoto T, Saijoh K, Fukase M, Chihara K (1994) Calcitonin directly acts on mouse osteoblastic Mc3T3-El cells to stimulate Mrna expression of c-Fos, insulin-like growth factor-1 and osteoblastic phenotypes (type 1 collagen and osteocalcin). Biochem Biophys Res Commun 199:876–880PubMedCrossRefGoogle Scholar
  10. 10.
    Szücs J, Horváth C, Kollin E, Szathmári M, Holló I (1992) Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue lnt 50:7–10CrossRefGoogle Scholar
  11. 11.
    Rico H, Revilla M, Hernández ER, Villa LF, Alvarez de Buergo M (1995) Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 56:181–185PubMedCrossRefGoogle Scholar
  12. 12.
    Rico H, Hernandez ER, Revilla M, Gómez-Castresana F (1992) Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131–138PubMedCrossRefGoogle Scholar
  13. 13.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis-a dose-response study. Br Med J 305:556–561CrossRefGoogle Scholar
  14. 14.
    Silverberg SJ, Bilezikian JP (1994) Parathyroid function and responsiveness in osteoporosis. In: Bilezikian JP, Marcus R, Levine MA (eds) Parathyroids: basic and clinic aspects. Raven Press, New York, pp 805–812Google Scholar
  15. 15.
    Wronski TJ, Yen CF (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15:51–58PubMedCrossRefGoogle Scholar
  16. 16.
    Ejersted C, Andreassen TT, Nilsson MHL, Oxlund H (1994) Human parathyroid hormone (1–34) increases bone formation and strength of cortical bone in aged rats. Bur J Endocrinol 130:201–207Google Scholar
  17. 17.
    Jerome CP ( 1994) Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J Bone Miner Res 9:933–942PubMedCrossRefGoogle Scholar
  18. 18.
    Mosekilde L, Sogaard CH, Mcosker JE, Wronski TJ (1994) PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate)-assessed in sexually mature, ovariectomized rats. Bone 15:401–408PubMedCrossRefGoogle Scholar
  19. 19.
    Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM (1994) Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618–1623PubMedCrossRefGoogle Scholar
  20. 20.
    Ettinger E, Genant HK, Steiger P, Madvig P (1992) Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 166:479–48PubMedCrossRefGoogle Scholar
  21. 21.
    Lufkin EG, Wahner HW, Ofallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1–9PubMedCrossRefGoogle Scholar
  22. 22.
    Marcus R (1993) Cyclic etidronate-Has the rose lost its bloom?. Am J Med 95:555–556PubMedCrossRefGoogle Scholar
  23. 23.
    Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J ( 1994) Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595–1599PubMedGoogle Scholar
  24. 24.
    Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118: 220–224PubMedGoogle Scholar
  25. 25.
    Boyce BF, Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT (1994) Mineralisation defects after pamidronate for Pagets disease. Lancet 343:1231–1232PubMedCrossRefGoogle Scholar
  26. 26.
    Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S (1994) Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833–1837PubMedCrossRefGoogle Scholar
  27. 27.
    Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V (1994) Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget’s disease of bone. Bone Miner 25:75–82PubMedCrossRefGoogle Scholar
  28. 28.
    Chesnut CH, Mcclung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryortillotson S, Santora AC (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144–152PubMedCrossRefGoogle Scholar
  29. 29.
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguezportales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443PubMedCrossRefGoogle Scholar
  30. 30.
    Rico H (1991) Minerals and osteoporosis. Osteoporosis Int 2:20–25CrossRefGoogle Scholar
  31. 31.
    Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM (1991) A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1:155–161CrossRefGoogle Scholar
  32. 32.
    Pak CYC, Sakhaee K, Adamshuet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401–408PubMedCrossRefGoogle Scholar
  33. 33.
    Marie PJ, Hott M, Modrowski D, Depollak C, Guillemain J, Deloffre P, Tsouderos V (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607–615PubMedCrossRefGoogle Scholar
  34. 34.
    Marie PJ, Hott M, Lomri A (1994) Regulation of endosteal bone formation and osteoblasts in rodent vertebrae. Cell Mater 4:143–154Google Scholar
  35. 35.
    Neufeld EB, Boskey AL (1994) Strontium alters the complexed acidic phospholipid content of mineralizing tissues. Bone 15:425–430PubMedCrossRefGoogle Scholar
  36. 36.
    Yamaguchi M, Hashizume M (1994) Effect of beta-alanyl-Lhistidinato zinc on protein components in osteoblastic MC3T3-El cells: increase in osteocalcin, insulin-like growth factor-! and transforming growth factor-beta. Mol Cell Biochem 136:163–169PubMedCrossRefGoogle Scholar
  37. 37.
    Moonga BS, Dempster DW (1995) Zinc is a potent inhibitor of osteoclastic bone resorption in vitro. J Bone Miner Res 10:453–457PubMedCrossRefGoogle Scholar
  38. 38.
    Strause L, Saltman P, Smith KT, Bracker M, Andon MB (1994) Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. J Nutr 124:1060–1064PubMedGoogle Scholar
  39. 39.
    Nielson FH, Hunt CD, Mullen LM, Hunt JR (1987) Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB J 1:394–397Google Scholar
  40. 40.
    Meacham SL, Taper LJ, Volpe SL (1994) Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes. Environ Health Perspect 102 (suppl 7):79–82PubMedCentralPubMedGoogle Scholar
  41. 41.
    Valente M, Bufalino L, Castiglione GN, Dangelo R, Mancuso A, Galoppi P, Zichella L (1994) Effects of 1-year treatment with Ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377–380PubMedCrossRefGoogle Scholar
  42. 42.
    Maugeri D, Panebianco P, Russo MS, Motta M, Tropea S, Motta L, Garozzo C, Lomeo E, Sangiorgi GB, Scuderi G, Carozzo M, Cantatore FP, Perpignano G, Ferraraccio A, Ennas F (1994) Ipriflavone treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 19:253–263PubMedCrossRefGoogle Scholar
  43. 43.
    Tyan ML (1993) Effect of promethazine on lumbar vertebral bone mass in postmenopausal women. J Intern Med 234: 143–148PubMedCrossRefGoogle Scholar
  44. 44.
    Sebastian A, Harris ST, Ottaway JH, Todd KM, Morris RC (1994) Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med 330:1776–1781PubMedCrossRefGoogle Scholar
  45. 45.
    Kraut JA, Coburn JW (1994) Bone, acid, and osteoporosis. N Engl J Med 330:1821–1822PubMedCrossRefGoogle Scholar
  46. 46.
    Lutz J (1984) Calcium balance and acid-base status of women as affected by increase protein intake and by sodium bicarbonate ingestion. Am J Clin Nutr 39:281–288PubMedGoogle Scholar
  47. 47.
    Middler S, Pak CYC, Murad F, Bartter F (1973) Thiazide diuretics and calcium metabolism. Metabolism 22: 139-146PubMedCrossRefGoogle Scholar
  48. 48.
    Malluche HH, Meyer-Sabellek W, Singer FR, Massry SG (1980) Evidence for a direct effect ofthiazides on bone. Miner Electrolyte Metab 4:89–96Google Scholar
  49. 49.
    Ray WA, Downey W, Griffin MR, Melton LJ (1989) Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1:687–690PubMedCrossRefGoogle Scholar
  50. 50.
    LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scgerr PA, George LK, Cornoni-Hentley J, Ostfeld AM (1990) Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 322:286–290PubMedCrossRefGoogle Scholar
  51. 51.
    Rico H, Revilla M, Villa LF, Arribas I, Alvarez del Buergo M (1993) A longitudinal study of total and regional bone mineral content and biochemical markers of bone resorption in patients with idiopathic hypercalciuria on thiazide treatment. Miner Electrolyte Metab 19:337–342PubMedGoogle Scholar
  52. 52.
    Hart JP, Catterall A, Dodds RA (1984) Circulating vitamin K levels in fractured neck of femur. Lancet 2:283PubMedCrossRefGoogle Scholar
  53. 53.
    Hart JP, Shearer MJ, Klenerman L, Caterrall A, Reeve J, Sambrook PN, Dods RA, Bitensky L, Chayen J (1985) Electrochemical detection of depressed circulating levels of vita-H. Rico: Perspectives for Treatment of Osteoporosis min K1 in osteoporosis. J Clin Endocrinol Metab 60:1268–1269PubMedCrossRefGoogle Scholar
  54. 54.
    Tsutsumi N, Kawashima K, Nagata H, Tsuyuki J, Itoh F, Arai N, Kojima M, Ujiie A, Endo H (1994) Effects of KCA-098 on bone metabolism: comparison with those of ipriflavone. Jpn J Pharmacol 65:343–349PubMedCrossRefGoogle Scholar
  55. 55.
    Tomita A (1971) Postmenopausal osteoporosis 47Ca study with vitamin K2. Clin Endocrinology 19:731–736Google Scholar
  56. 56.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin-D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642PubMedCrossRefGoogle Scholar
  57. 57.
    Rico H, Revilla M (1994) Papel del calcio en la osteoporosis. Ann Med Intern (Madrid) 11:604–609Google Scholar
  58. 58.
    Rico H, Cabranes JA, Hernandez ER, Perez del Molino J, Escudero G (1990) Effect of calcium pidolate on biochemical and hormonal parameters in involutional osteoporosis. Maturitas 12:105–111PubMedCrossRefGoogle Scholar
  59. 59.
    Horowitz M, Need AG, Morris HA, Wishart J, Nordin BEC (1988) Biochemical effects of calcium supplementation in postmenopausal osteoporosis. Eur J Clin Nutr 42:775–778PubMedGoogle Scholar
  60. 60.
    Rico H, Revilla M, Villa LF, Alvarez de Buergo M, Arribas I (1994) Longitudinal study of the effect of calcium pi do late on bone mass in eugonadal women. CalcifTissue Int 54:477–480Google Scholar
  61. 61.
    Johnston CC, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, Peacock M (1992) Calcium supplementation and increases in bone mineral density in children. N Engl J Med 327:82–87PubMedCrossRefGoogle Scholar
  62. 62.
    Filipponi P, Mannarelli C, Pacifici R, Grossi E, Moretti I, Tini S, Carloni C, Blass A, Morucci P, Hrruska KA, Avioli LV (1988) Evidence for a prostaglandin-mediated bone resorptive mechanism in subjects with fasting hypercalciuria. Calcif Tissue Int 43:61–66PubMedCrossRefGoogle Scholar
  63. 63.
    Bell NH, Hollis BW, Shary JR, Eyre DR, Eastell R, Colwell A, Russell RGG (1994) Diclofenac sodium inhibits bone resorption in postmenopausal women. Am J Med 96:349–353PubMedCrossRefGoogle Scholar
  64. 64.
    Oursler MJ, Spelsberg TC (1993) Echistatin, a potential new drug for osteoporosis (Editorial) Endocrinology 132:939–940PubMedGoogle Scholar
  65. 65.
    Rouffet J, Coxam V, Gaumet N, Barlet JP (1994) Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments}. Reprod Nutr Dev 34:473–481PubMedCrossRefGoogle Scholar
  66. 66.
    Zheng MH, Mccaughan HB, Papadimitriou JM, Nicholson GC, Wood DJ (1994) Tartrate-resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (Osteostatin) from parathyroid hormone-related protein. J Cell Biochem 54:145–153PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1997

Authors and Affiliations

  • H. Rico
    • 1
  1. 1.Department of MedicineUniversity of Alcala de HenaresMadridSpain

Personalised recommendations